Cybrexa Therapeutics

Cybrexa is a clinical stage, oncology-focused, platform-technology company that enables antigen independent targeting of tumors and metastases with deep tissue penetration for small molecule anti-cancer drugs. Its proprietary alphalexTM pH targeting technology is based on the Warburg effect, was developed in Dr. Don Engleman’s lab at Yale. Cybrexa’s technology is an alternative approach to antibody-drug conjugates (ADC’s) for targeting tumors with the advantage of not requiring a tumor-specific, internalizing, cell membrane target.